• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤维蛋白原与纤溶酶抑制剂的关联,而非凝血因子 XIII 基因多态性与冠状动脉疾病的关联。

Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease.

作者信息

Bronić Ana, Ferenčak Goran, Bernat Robert, Leniček-Krleža Jasna, Dumić Jerka, Dabelić Sanja

机构信息

Sestre Milosrdnice University Hospital Centre, Clinical Institute of Chemistry, Department for Laboratory Diagnostics in Traumatology and Orthopaedics, Zagreb, Croatia.

Medicol Outpatients Clinic, Department of Laboratory Diagnostics, Zagreb, Croatia.

出版信息

J Med Biochem. 2021 Mar 12;40(2):138-149. doi: 10.5937/jomb0-26839.

DOI:10.5937/jomb0-26839
PMID:33776563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7982289/
Abstract

BACKGROUND

In the final phase of clot formation, fibrinogen constitutes frame, whereas factor XIII (FXIII) active form is responsible for the covalent cross-linking of fibrin fibres and plasmin inhibitor (PI), thus contributing to clot stability. It could be expected that any change of coagulation factors' structure affects the clot formation and modulates the atherothrombotic risk. The aim was to determine the frequency of four single nucleotide polymorphisms: () A > G in codon 312 of the fibrinogen α-chain gene (rs6050, Thr312AlaFGA), () C > T at position 10034 of the 3 - untranslated region in the fibrinogen γ-chain gene (rs2066865, 10034C > T FGG), () C > T in codon 564 of the FXIII-A subunit gene (rs5982, Pro564LeuFXIII-A), and () C > T in codon 6 of the plasmin inhibitor gene (rs2070863, Arg6TrpPI) in Croatian patients and their association with coronary artery disease (CAD).

METHODS

We performed the unrelated case-control association study on the consecutive sample of patients 18 years old, who had undergone coronary angiography for investigation of chest pain and suspected CAD. The cases were patients with confirmed CAD (N=201), and the controls were the subjects with no CAD (N=119). Samples were genotyped using PCR-RFLP analysis.

RESULTS

Observed frequencies of the rare alleles of Thr312Ala FGA, 10034C > T FGG, Leu564Pro FXIII-A and Arg6Trp PI polymorphisms were 21%, 17%, 14%, 20%, respectively. Patients with 10034C > T FGG CC genotype had 3.5 times (95% CI 1.02-12.03) higher adjusted odds for CAD than patients with 10034C > T FGG TT genotype. Patients with Arg6Trp PI CC genotype had 3.86 times (95% CI 1.23-12.12) higher odds for CAD than patients with Arg6Trp PI TT genotype. It seems that those genotype-related higher odds are also male-gender related. No difference was observed regarding any other investigated polymorphism.

CONCLUSIONS

Our finding suggests that 10034C > T FGG and Arg6Trp PI are associated with CAD.

摘要

背景

在凝血的最后阶段,纤维蛋白原构成框架,而因子 XIII(FXIII)的活性形式负责纤维蛋白纤维和纤溶酶抑制剂(PI)的共价交联,从而有助于凝块稳定。可以预期,凝血因子结构的任何变化都会影响凝血形成并调节动脉粥样硬化血栓形成风险。目的是确定克罗地亚患者中四个单核苷酸多态性的频率:()纤维蛋白原α链基因密码子312处的A>G(rs6050,Thr312Ala FGA),()纤维蛋白原γ链基因3'非翻译区第10034位的C>T(rs2066865,10034C>T FGG),()FXIII-A亚基基因密码子564处的C>T(rs5982,Pro564Leu FXIII-A),以及()纤溶酶抑制剂基因密码子6处的C>T(rs2070863,Arg6Trp PI)及其与冠状动脉疾病(CAD)的关联。

方法

我们对1,8岁因胸痛和疑似CAD接受冠状动脉造影的连续患者样本进行了非亲属病例对照关联研究。病例为确诊CAD的患者(N=201),对照为无CAD的受试者(N=119)。使用PCR-RFLP分析对样本进行基因分型。

结果

Thr312Ala FGA、10034C>T FGG、Leu564Pro FXIII-A和Arg6Trp PI多态性罕见等位基因的观察频率分别为21%、17%​、14%、20%。具有10034C>T FGG CC基因型的患者患CAD的校正比值比具有10034C>T FGG TT基因型的患者高3.5倍(95%CI 1.02-12.03)。具有Arg6Trp PI CC基因型的患者患CAD的比值比具有Arg6Trp PI TT基因型的患者高3.86倍(95%CI 1.23-12.12)。似乎这些与基因型相关的较高比值比也与男性性别相关。在任何其他研究的多态性方面未观察到差异。

结论

我们的发现表明10034C>T FGG和Arg6Trp PI与CAD相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecfd/7982289/a07778f5914d/jomb-40-2-2102138B-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecfd/7982289/b43d82452a50/jomb-40-2-2102138B-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecfd/7982289/a07778f5914d/jomb-40-2-2102138B-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecfd/7982289/b43d82452a50/jomb-40-2-2102138B-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecfd/7982289/a07778f5914d/jomb-40-2-2102138B-g002.jpg

相似文献

1
Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease.纤维蛋白原与纤溶酶抑制剂的关联,而非凝血因子 XIII 基因多态性与冠状动脉疾病的关联。
J Med Biochem. 2021 Mar 12;40(2):138-149. doi: 10.5937/jomb0-26839.
2
The fibrinogen gamma 10034C>T polymorphism is not associated with Peripheral Arterial Disease.纤维蛋白原γ 10034C>T 多态性与外周动脉疾病无关。
Thromb Res. 2010 Oct;126(4):350-2. doi: 10.1016/j.thromres.2010.07.007. Epub 2010 Aug 14.
3
Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio.多态性10034C>T位于调控FGG转录本聚腺苷酸化的区域,影响纤维蛋白原γ'/γA mRNA比例。
J Thromb Haemost. 2007 Jun;5(6):1243-9. doi: 10.1111/j.1538-7836.2007.02566.x.
4
The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis.纤维蛋白原γ(FGG)10034C>T多态性与静脉血栓形成相关。
Thromb Res. 2007;121(1):33-6. doi: 10.1016/j.thromres.2007.03.007. Epub 2007 Apr 19.
5
Fibrinogen beta variants confer protection against coronary artery disease in a Greek case-control study.纤维蛋白原β变体可降低希腊病例对照研究人群的冠心病风险。
BMC Med Genet. 2010 Feb 18;11:28. doi: 10.1186/1471-2350-11-28.
6
Fibrinogen β chain and FXIII polymorphisms affect fibrin clot properties in acute pulmonary embolism.纤维蛋白原β链和FXIII基因多态性影响急性肺栓塞中的纤维蛋白凝块特性。
Eur J Clin Invest. 2022 Apr;52(4):e13718. doi: 10.1111/eci.13718. Epub 2021 Nov 21.
7
Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.α2-纤溶酶抑制剂在纤维蛋白凝块中的掺入及其与急性缺血性脑卒中患者临床转归的关系。
Biomolecules. 2021 Feb 25;11(3):347. doi: 10.3390/biom11030347.
8
Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease.患有冠状动脉疾病的凝血因子XIII A亚基Leu34纯合患者的凝血因子XIII水平降低。
Thromb Res. 2008;121(4):469-76. doi: 10.1016/j.thromres.2007.05.012. Epub 2007 Jun 27.
9
Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction.纤维蛋白原和凝血因子 XIII 基因多态性对血浆纤维蛋白原浓度、纤维蛋白凝胶结构及心肌梗死风险的上位性和多效性影响。
Thromb Haemost. 2006 Mar;95(3):420-7. doi: 10.1160/TH05-11-0777.
10
Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.因子 XIII Val34Leu 多态性作为严重冠状动脉疾病患者纤维蛋白凝块通透性和抗溶解能力的调节剂。
Kardiol Pol. 2009 Aug;67(8A):947-55.

引用本文的文献

1
Susceptibility of MMP3 gene polymorphism to coronary artery disease: A meta-analysis.基质金属蛋白酶3基因多态性与冠状动脉疾病的易感性:一项荟萃分析。
J Med Biochem. 2023 Oct 27;42(4):685-693. doi: 10.5937/jomb0-43315.
2
Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target.健康与糖尿病中的纤溶酶抑制剂:该蛋白作为治疗靶点的作用
TH Open. 2022 Nov 18;6(4):e396-e407. doi: 10.1055/a-1957-6817. eCollection 2022 Oct.
3
ADS Score as a Novel Predictor of Outcomes in Patients Who Underwent Percutaneous Coronary Intervention.

本文引用的文献

1
Fibrinogen gamma gene and risk of cancer-related venous thromboembolism.纤维蛋白原γ基因与癌症相关静脉血栓栓塞风险。
Haematologica. 2020 Jul;105(7):1963-1968. doi: 10.3324/haematol.2019.224279. Epub 2019 Oct 3.
2
Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.蛋白水解和非蛋白水解激活机制导致凝血因子 XIII A 呈现构象和功能不同的形式。
FEBS J. 2020 Feb;287(3):452-464. doi: 10.1111/febs.15040. Epub 2019 Aug 28.
3
Understanding myocardial infarction.
ADS评分作为接受经皮冠状动脉介入治疗患者预后的新型预测指标。
Front Cardiovasc Med. 2021 Dec 13;8:720597. doi: 10.3389/fcvm.2021.720597. eCollection 2021.
4
Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.纤维蛋白原和抗纤维蛋白溶酶蛋白:相互作用和未来的治疗策略。
Int J Mol Sci. 2021 Nov 21;22(22):12537. doi: 10.3390/ijms222212537.
了解心肌梗死。
F1000Res. 2018 Sep 3;7. doi: 10.12688/f1000research.15096.1. eCollection 2018.
4
The role of β-barrels 1 and 2 in the enzymatic activity of factor XIII A-subunit.β-桶 1 和 2 在因子 XIII A 亚基酶活性中的作用。
J Thromb Haemost. 2018 Jul;16(7):1391-1401. doi: 10.1111/jth.14128. Epub 2018 May 27.
5
Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.动脉粥样硬化血栓形成和血栓栓塞:第二次马斯特里赫特血栓形成共识会议立场文件。
Thromb Haemost. 2018 Feb;118(2):229-250. doi: 10.1160/TH17-07-0492. Epub 2018 Jan 29.
6
Inhibition of Fibrinolysis by Coagulation Factor XIII.凝血因子 XIII 对纤维蛋白溶解的抑制作用。
Biomed Res Int. 2017;2017:1209676. doi: 10.1155/2017/1209676. Epub 2017 Jul 6.
7
Associations between polymorphisms in coagulation-related genes and venous thromboembolism: A meta-analysis with trial sequential analysis.凝血相关基因多态性与静脉血栓栓塞症之间的关联:一项采用序贯试验分析的荟萃分析
Medicine (Baltimore). 2017 Mar;96(13):e6537. doi: 10.1097/MD.0000000000006537.
8
Fibrinogen and Fibrin in Hemostasis and Thrombosis.止血与血栓形成中的纤维蛋白原和纤维蛋白
Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):e13-e21. doi: 10.1161/ATVBAHA.117.308564.
9
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease.对基因多效性的系统评估确定了另外6个与冠状动脉疾病相关的基因座。
J Am Coll Cardiol. 2017 Feb 21;69(7):823-836. doi: 10.1016/j.jacc.2016.11.056.
10
Fibrinogen splice variation and cross-linking: Effects on fibrin structure/function and role of fibrinogen γ' as thrombomobulin II.纤维蛋白原剪接变异和交联:对纤维蛋白结构/功能的影响及纤维蛋白原γ'作为血栓调节素 II 的作用。
Matrix Biol. 2017 Jul;60-61:8-15. doi: 10.1016/j.matbio.2016.09.010. Epub 2016 Oct 23.